Previous Article | Next Article 
Molecular and Cellular Biology, September 1999, p. 5969-5980, Vol. 19, No. 9
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Impaired Immune Responses and B-Cell
Proliferation in Mice Lacking the Id3 Gene
Lihua
Pan,1
Shinichi
Sato,1,
Joshua P.
Frederick,2
Xiao-Hong
Sun,3 and
Yuan
Zhuang1,*
Department of
Immunology1 and Department of
Pharmacology and Cancer Biology,2 Duke
University Medical Center, Durham, North Carolina 27710, and
Department of Cell Biology, New York University Medical
Center, New York, New York 100163
Received 26 February 1999/Returned for modification 13 April
1999/Accepted 8 June 1999
 |
ABSTRACT |
B-lymphocyte activation and proliferation induced by the B-cell
receptor (BCR) signals are important steps in the initiation of humoral
immune responses. How the BCR signals are translated by nuclear
transcription factors into cell cycle progression is poorly understood.
Id3 is an immediate-early gene responding to growth and
mitogenic signals in many cell types including B cells. The primary
function of the Id3 protein has been defined as that of inhibitor of
basic-helix-loop-helix (bHLH) transcription factors. The interaction
between Id3 and bHLH proteins, many of which are essential for cellular
differentiation, has been proposed as a key regulatory event leading to
cellular proliferation instead of differentiation. To further
investigate the role of Id3 in tissue and embryo development and the
mechanism of Id3-mediated growth regulation, we generated and analyzed
Id3-deficient mice. While these mice display no overt
abnormality in tissue and embryo development, their humoral immunity is
compromised. The amounts of immunoglobulins produced in
Id3-deficient mice immunized with a T-cell-dependent
antigen and a type 2 T-cell-independent antigen are attenuated and
severely impaired, respectively. Further analysis of lymphocytes
isolated from Id3-deficient mice reveals a B-cell defect in
their proliferation response to BCR cross-linking but not to
lipopolysaccharide or a combination of BCR cross-linking and
interleukin-4. Analyses of cultured lymphocytes also suggest involvement of Id3 in cytokine production in T cells and isotype switching in B cells. Finally, the proliferation defect in
Id3-deficient B cells can be rescued by ectopic expression
of Id1, a homologue of Id3. Taken together,
these results define a necessary and specific role for Id3 in mediating
signals from BCR to cell cycle progression during humoral immune responses.
 |
INTRODUCTION |
The basic-helix-loop-helix (bHLH)
family proteins play pivotal roles in cell growth and differentiation
(31). Most of the bHLH proteins can bind to DNA via the
basic region located N-terminal to the HLH domain. Dimerization between
two bHLH proteins, which is a prerequisite for DNA binding, is mediated
by their HLH domains (45, 46, 63). Most bHLH proteins have
been classified into three groups: the E-proteins, the tissue-specific
bHLH proteins, and the dominant negative Id proteins. The E proteins,
including E12/E47 (E2A gene products), E2-2, and HEB, are characterized by their non-tissue-specific expression patterns and their ability to
form homodimers and heterodimers with members of the other two groups.
Most bHLH proteins, such as members of the MyoD family in muscle cells
(20), MASH-1 in neuronal cells (33), and LYL-1 in
lymphopoietic cells (39), are tissue specific. These
tissue-specific bHLH proteins preferentially form heterodimers with
E proteins and control specific differentiation events in the resident
cell types (31, 64).
The Id proteins are characterized by lacking the basic DNA-binding
domain while retaining the HLH dimerization domain (6). Id
proteins preferentially dimerize with the E proteins and consequently prevent the heterodimers from binding to DNA and activating
transcription of target genes (32). A role for Id proteins
in cell differentiation and development is best demonstrated by the
Drosophila Extramacrochaetae (emc) protein
(21, 26), which negatively regulates sensory-organ development, presumably by antagonizing the activity of bHLH proteins encoded by the achaete-scute genes (21). Mammals
have four Id genes, namely, Id1 (6),
Id2 (7, 60), Id3 (11, 18), and Id4 (48). All four Id genes are
broadly but non-uniformly expressed (48). In general, the
expression level of Id genes is high in proliferating cells
and low in differentiating cells and quiescent cells. Intensive studies
in the past have led to the notion that Id proteins act as
differentiation inhibitors by directly antagonizing the function of
bHLH proteins (1, 19, 32, 40, 55, 60).
The Id3 gene, also known as HLH462 and
HLHIR21, was cloned from mouse fibroblasts (and
independently from human B cells) based on its immediate-early response
to mitogenic signals (11, 17, 44). Like other Id
genes, Id3 expression is high in proliferating cells, down
regulated in cells undergoing differentiation, and low in quiescent
cells (1, 17, 40, 42). A potential role for Id3
in tumorogenesis has been raised by the observed chromosomal translocations at the Id3 locus (termed Heir-1)
in human neuroblastoma (22, 65). The function of Id3
proteins as differentiation inhibitors was proposed and supported by
the studies of ectopic expression of Id3 in various cell
types including myoblast and preadipocyte (1, 40, 42). Id3
was also shown to promote NK-cell differentiation at the expense of
T-lineage cells in a fetal thymus organ culture test (30).
Recent evidence shows that phosphorylation of Id3 and Id2 by
cyclin-dependent kinase 2 (CDK-2) affects their abilities to inhibit
the formation of different bHLH complexes (18, 28).
Therefore, the differentiation-inhibitory activity of Id3 may be
regulated at both the transcriptional and posttranslational levels.
Compelling evidence indicates that B-cell development is tightly
regulated by E proteins and Id proteins. Forced expression of E47, a
product of E2A, can initiate the immunoglobulin (Ig) heavy-chain
rearrangement in a pre-T-cell line (52) and several nonlymphoid cell lines (32). In contrast, ectopic expression of Id1 represses the activity of Ig heavy-chain enhancer through antagonizing the DNA-binding activity of E2A proteins (66). These results were later confirmed by the studies of E2A-deficient mice
and Id1 transgenic mice, both of which display severe
defects in pro-B-cell development (3, 59, 72). It has been
proposed that E47, in collaborating with E12, supports the B-lineage
commitment and subsequent differentiation events (2, 70)
while Id proteins may negatively regulate these processes through
antagonizing the E proteins. However, how and when each individual
Id gene is involved in B-cell development is not clear.
E2A and Id proteins have also been implicated in B-cell maturation. E2A
proteins were detected in all stages of B-cell development (67). Immunostaining also revealed an upregulation of E2A in the dark zone of the germinal center, where hypermutation and isotype
switching occur (27, 49). Ectopic expression of
Id1 in a mature B-cell line inhibited the ability of cells
to undergo spontaneous isotype switching, suggesting a functional
interaction between Id and E2A proteins (27). However, a
role for Id1 or Id2 in mature B cells is
questioned by their reduced levels of expression in mature B cells
(60, 66). A recent study on Id1-deficient mice
showed a normal B-cell development in the absence of Id1 (68). Because Id3 is expressed throughout B-cell
development except the plasma cell stage (41), an
investigation of Id3 may help to understand how bHLH
proteins control B-cell differentiation and maturation.
We report here the generation and analysis of Id3-deficient
(Id3
/
) mice. Id3
/
mice displayed no obvious developmental abnormalities and contained a
normal number of B and T lymphocytes. However, these mice had reduced
levels of IgG1 and IgG2a in serum prior to immunization, a severely
impaired immune response to DNP-Ficoll (a type 2 T-independent antigen,
TI-2), and an attenuated ability to switch to IgG2a and IgG3 isotypes
when challenged with keyhole limpet hemocyanin (KLH) coupled to DNP (a
T-dependent antigen [TD]). B cells isolated from
Id3
/
mice further showed a proliferation
defect in response to surface IgM engagement but not to stimulation
with lipopolysaccharide (LPS), CD38, CD40, IgM plus interleukin-4
(IL-4), and phorbol myristate acetate (PMA) plus ionomycin. This
proliferation defect can be rescued by introduction of an
Id1 transgene into the B-lymphoid lineage. These studies
reveal a specific role for Id3 in B-cell proliferation and humoral
immunity and indicate the existence and importance of other bHLH
proteins in B-cell immunity.
 |
MATERIALS AND METHODS |
Targeting vector.
The Id3 gene was isolated after
probing a 129/SV genomic library with a mouse Id3 cDNA. The
PstI-XhoI fragment covering the first two exons
and part of the third exon was replaced by a PGKneo expression
cassette. The PGKtk gene was placed at the 5' end of the targeting
vector to provide a selection against nonhomologous recombination.
ES cell culture and generation of mutant mice.
Linearized
targeting construct (25 µg) was electroporated into AK7 embryonic
stem (ES) cells (a gift from A. Imamoto and P. Soriano, Fred Hutchinson
Cancer Research Center, Seattle, Wash.). The cells were grown under
double selection with G418 and ganciclovir. Correct targeting events
were found in 8 of 60 clones screened by PCR.
Id3+/
ES cells were injected into C57BL/6
blastocysts, which were then transferred into pseudopregnant mothers.
Germ line transmission was obtained from one of three clones injected.
Mice carrying the mutant Id3 allele were intercrossed, and
all immune system assays were performed with 6 to 12-week-old mice
derived from the 129/SV-C57BL/6 mixed background.
Southern and Northern blot analysis.
Southern blot analysis
was performed by separating genomic DNA on a 1% agarose gel after
SacI restriction enzyme digestion. Blotting and
hybridization were performed with a Nytran membrane (Schleicher & Schuell, Keene, N.H.) under the conditions recommended by the
manufacturer. The Southern probe was a 0.7-kb
XhoI-HindIII fragment isolated from the
Id3 gene (see Fig. 1A). Northern blot analysis was performed
by separating RNA on 1.2% agarose gels in the presence of formaldehyde
followed by blotting to a Nytran membrane. RNA was isolated from
splenocytes by an RNAzol (Tel-Test Inc., Friendswood, Tex.) extraction
as specified by the manufacturer. Erythrocytes were depleted from the
splenocyte preparation by ammonium chloride (0.017 M Tris · HCl
[pH 7.65], 0.16M NH4Cl) treatment prior to RNA
extraction. Id3, Id2, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mouse cDNAs were
used as probes in hybridization under the conditions recommended by the
manufacturer (Schleicher & Schuell). Radiation signals were detected
with a STORM 840 PhosphorImager (Molecular Dynamics, Sunnyvale, Calif.)
and analyzed with the ImageQuant program provided by the manufacturer.
Flow cytometry analysis.
Single-cell suspensions of
lymphocytes from the thymus, spleen, bone marrow, peripheral lymph
nodes, and peritoneal cavity were prepared in ice-cold
phosphate-buffered saline supplemented with 5% bovine calf serum.
Splenocytes were depleted of erythrocytes by ammonium chloride lysis
before use. All the suspensions were counted with a hemocytometer, and
106 cells were stained immediately with a combination of a
fluorescein isothiocyanate (FITC)-conjugated antibody, a phycoerythrin
(PE)-conjugated antibody, and 7-amino-actinomycin D (7AAD) (Molecular
Probes, Eugene, Oreg.). The cells were washed once with
phosphate-buffered saline-bovine calf serum and analyzed on a FACScan
flow cytometer (Becton Dickinson, San Jose, Calif.). Data from
104 cells were collected and analyzed with the CellQuest
program (Becton Dickinson, San Jose, Calif.). Antibodies used in this study included biotinylated or FITC-conjugated anti-B220 (RA3-6B2; Caltag, Burlingame, Calif.), FITC-conjugated anti-CD43 (S7; PharMingen, San Diego, Calif.), biotinylated or FITC-conjugated goat anti-mouse IgM
isotype-specific antibodies (Southern Biotechnology Associates, Inc.,
Birmingham, Ala.), biotinylated goat anti-mouse IgD isotype-specific antibodies (Southern Biotechnology Associates, Inc.), PE-conjugated anti-mouse I-Ab (AF6-120.1; PharMingen), anti-CD21/35 (7E9; provided by
T. Tedder, Duke University, Durham, N.C.), PE-conjugated anti-CD23 (B3B4; PharMingen), PE-conjugated anti-CD4 (CT-CD4; Caltag),
anti-CD8
(CT-CD8b; Caltag), PE-conjugated anti-CD5 (53-7.3;
PharMingen), and PE-conjugated anti-MAC-1 (F4/80; Caltag).
PE-conjugated streptavidin (Jackson ImmunoResearch Laboratories, Inc.,
West Grove, Pa.) was used to reveal biotin-coupled antibody staining.
Dead and damaged cells stained positive for 7AAD and were eliminated
from the analysis.
Serum Ig isotype-specific ELISAs.
Ig levels in serum were
determined by an isotype-specific enzyme-linked immunosorbent assay
(ELISA) as described previously (21). Briefly, ELISA plates
were coated with antibodies against mouse Igs (Southern Biotechnology
Associates, Inc). A standard curve was generated by using
affinity-purified monoclonal antibodies against mouse IgM, IgG1, IgG2a,
IgG2b, IgG3, and IgA (Southern Biotechnology Associates, Inc.). The Ig
concentration for each individual sample was determined by comparing
the mean optical density values from duplicate wells to the standard
curve. DNP-specific antibody titers were measured by coating ELISA
plates with DNP-bovine serum albumin (Calbiotech-Novabiochem Corp., La
Jolla, Calif.). Sera were diluted and assessed for relative Igs as
above. The statistical analysis was performed by Student's
t test.
Immunization.
Mice (2 to 3 months old) were immunized
intraperitoneally (i.p.) with 25 µg of DNP-Ficoll (Biosearch
Technologies, San Rafael, Calif.) in saline and were bled from the
retroorbital venous plexus on days 0, 7, and 14 after immunization. For
thymus-dependent immunization, mice (2 to 3 months old) were immunized
i.p. with 100 µg of DNP-KLH (Calbiotech-Novabiochem Corp.) in
complete Freund's adjuvant on day 0 and boosted without adjuvant 21 days later. Blood samples were collected on days 0, 7, 21, and 28.
Calcium influx assay.
Erythrocyte-depleted splenocytes were
prepared at 107/ml in RPMI 1640 medium (containing 5%
bovine calf serum and 10 mM HEPES) and incubated with 1 mM Indo-1 AM
(Molecular Probes, Eugene, Oreg.) for 40 min at 37°C as previously
described (14). Calcium influx was triggered by adding
MB19-1 (51) at 70 µg/ml or affinity-purified goat
F(ab')2 antibody fragments to mouse IgM (Cappel, Durham, N.C.) at 10 or 40 µg/ml to 2 × 106/ml Indo-1-loaded
cells. The intracellular Ca2+ concentration
([Ca2+]i) was determined by calculating the
ratio of Indo-1 fluorescence emission at 405 nm and at 525 nm with a
FACStar flow cytometer and LYSYS II software (Becton Dickinson).
Fluorescence ratios were recorded for 60 s before and 400 s
after antibody addition.
B-cell activation in culture.
Purified B cells were
incubated with 10 µg of F(ab')2 fragment of goat
anti-mouse IgM antibody (Cappel) per ml, 10 µg of LPS (Escherichia coli serotype O111:B4; Sigma, St. Louis, Mo.)
per ml, or medium alone for 24 h. B-cell activation was assessed
by fluorescence-activated cell sorter (FACS) analysis with
PE-conjugated anti-mouse I-Ab (AF6-120.1; PharMingen), FITC-conjugated
anti-CD69 (H1.2F3; PharMingen), and PE-conjugated anti-CD44 (IM7; PharMingen).
B- and T-cell purification.
B cells were purified from
splenocyte suspension by removing erythrocytes with ammonium chloride
and T cells with Thy1.2-coated magnetic beads (Dynal, Lake Success,
N.Y.). T cells were purified from inguinal and axillary lymph nodes or
spleen by using a T-cell enrichment column (R&D Systems, Minneapolis,
Minn.). The purity of B or T cells was greater than 92% in most cases
as determined by flow cytometry analysis of aliquots of purified cells
with PE-conjugated anti-T-cell receptor
/
(H57-597; Sigma) and
FITC-conjugated anti-B220 (RA3-6B2; Caltag).
B- and T-cell proliferation.
Purified B and T cells were
cultured in triplicate in 96-well flat-bottom tissue culture plates
(2 × 105 cells in 0.2 ml per well) under one of the
following conditions: 10 or 20 µg of F(ab')2 fragment of
goat anti-mouse IgM antibody per ml, 50 or 100 U of recombinant mouse
IL-4 (PharMingen) per ml plus 5 µg of F(ab')2
fragment of goat anti-mouse IgM antibody per ml, 20 µg of LPS
(E. coli serotype O111:B4), 10 µg of anti-CD40 monoclonal
antibody (HM40-3; PharMingen) per ml, 2 µg of concanavalin A (ConA)
(Sigma) per ml, or 20 ng of PMA (Sigma) per ml plus 1 µg of ionomycin
(Sigma) per ml. T-cell receptor stimulation was carried out by coating
plates with 10 µg of anti-CD3 monoclonal antibody clone 2C11
(PharMingen) per ml for 4 h at 4°C. Proliferation was measured
by [3H]thymidine incorporation (1 µCi per well) during
the last 16 h of a 64-h incubation.
In vitro isotype-switching assay.
Purified splenic B cells
were cultured in triplicate in 96-well flat-bottom tissue culture
plates (5 × 104 cells in 0.2 ml per well) for 6 days
in the presence of various stimuli. LPS (20 µg/ml) was added to the
culture on day 0. IL-4 (200 or 1,000 U/ml) was added 24 h after
the culture started. The concentrations of Ig isotypes in the culture
supernatants were determined by ELISA.
RNase protection analysis of cytokine expression.
Erythrocyte-depleted splenocytes (107) were prepared at
5 × 106/ml in medium and stimulated with 2.5 µg of
anti-CD3 per ml for 48 h as previously described (16).
Total RNA was isolated from cultured cells by using RNAzol. Cytokine
RNA levels were assessed by RNase protection assays with a RiboQuant
multiprobe kit (45024k/mCK-1; PharMingen). Radiation signals were
analyzed with the ImageQuant program.
RT-PCR assay.
Purified splenic B cells were incubated with
10 µg of F(ab')2 fragment of goat anti-mouse IgM antibody
per ml for various periods. Total cellular RNA was isolated from
incubated cells by using RNAzol and used for cDNAs synthesis as
previously described (50). Briefly, 100 to 200 ng of
isolated RNA was incubated with Moloney murine leukemia virus reverse
transcriptase (RT) (GIBCO BRL) for 5 min at room temperature and 30 min
at 55°C in a buffer containing 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 3 mM MgCl2, 0.1 mg of bovine serum albumin per ml, 10 mM
dithiothreitol, 0.5 mM each deoxynucleoside triphosphate, 10 U of
RNasin (Roche Molecular Systems, Inc., Branchburg, N.J.), and 100 pmol
of random hexamer primers. A fraction of the reverse transcription
product was used in each of the following PCRs. Elongation factor 1 alpha (EF1
) is detected as a 228-bp PCR product with primers YZ95
(5'-AGTTTGAGAAGGAGGCTGCT-3') and YZ95
(5'-CAACAATCAGGACAGCACAGTC-3'). Id3 is 192 bp with primers YZ132 (5'-GGGATCCGGGTCAGTGGCAAAAGCTCCT-3') and YZ155
(5'-CGAGGCACTCAGCTTAGCAG-3'). E2A is 185 bp with primers E7
(5'-CTAGCCCCTCAACGCCTGTG-3') and E15
(5'-CGGTGCCAACAGCGTGGCT-3'). c-Myc is 548 bp with primers c-myc1 (5'-AGTCCATTGATCCCTCAGTGGTCTTTCCCTA-3') and c-myc2
(5'-CAGCTCGTTCCTCCTCTGACGTTCCAAGACG-3') (58). PCR
was carried out in 15 µl of buffer containing 10 mM Tris-HCl (pH
8.4), 50 mM KCl, 1.5 mM MgCl2, 0.5 mM each deoxynucleoside triphosphate, 1 µCi of [
-32P]dCTP (3,000 Ci/mmol;
ICN), 0.5 µM each primer, and 1 U of Taq polymerase (GIBCO
BRL). The samples were denatured at 95°C for 5 min and cycled through
94°C for 45 s, 57°C for 45 s, and 72°C for 1 min for a
total of 21 to 33 times. Half of the PCR sample was electrophoresed on
5% polyacrylamide gels, and the PCR fragments were visualized by
autoradiography. Quantitation was performed with a STORM 840 PhosphorImager. EF1
was used as an internal control for RNA input.
Linear amplification was determined by running PCR reaction with at
least three incremental cycle conditions for each primer pairs. The
optimal number of cycles for each primer pair is 23 cycles for EF1
,
32 cycles for Id3, 30 cycles for E2A, and 32 cycles for c-Myc.
 |
RESULTS |
Generation of Id3-deficient mice.
The mouse
Id3 gene was disrupted in ES cells by replacing the first
two exons, which encode the entire translated sequence, and a portion
of the third exon with a neomycin resistance gene cassette (Fig.
1A). Successful targeting of the
Id3 gene was confirmed by Southern blot analysis of genomic
DNA with SacI, which produces 3.6- and 15-kb fragments for
wild-type and Id3 mutant alleles, respectively (Fig. 1B).
Northern blot analysis of total RNA from spleen showed the absence of
Id3 expression in homozygous Id3
/
mice while Id2 expression was unchanged (Fig. 1C).
Id1 expression in the spleen is undetectable by Northern
analysis for both wild type and Id3
/
mice
(data not shown). Id3
/
mice were recovered
with a Mendelian ratio from the heterozygous breeding (25%
Id3+/+, 52% Id3+/
,
23% Id3
/
; n = 124),
indicating that embryonic development is not affected by Id3
disruption. Further, Id3
/
mice are
superficially indistinguishable from their
Id3+/+ and Id3+/
littermates with respects to appearance, general behavior, body and
organ size, fertility, and mortality rate.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Diagrams of the mouse Id3 genomic locus
(top), the gene-targeting construct (middle), and the Id3
knockout allele (bottom). Exons and selection markers are indicated by
solid and open boxes, respectively. The probe used for Southern
analysis is shown. Restriction enzymes and selection markers are
abbreviated as follows: B, BamHI; H, HindIII;
P, PstI; S, SacI; X, XbaI; Xh,
XhoI; PGK, phosphoglycerate kinase gene promoter; tk,
thymidine kinase gene; neo, neomycin resistance gene. (B) Southern blot
analysis of genomic DNA from Id3+/+,
Id3+/ , and Id3 /
mice. DNA was digested with SacI and hybridized with the
probe shown in panel A. The sizes of SacI fragments for
wild-type and mutant alleles are 3.6 and 15 kb, respectively. (C)
Northern blot analysis of RNA isolated from
Id3+/+, Id3+/ , and
Id3 / mouse splenocytes. Probes used in
hybridization are indicated on the left, with GAPDH as a loading
control.
|
|
Normal lymphoid development.
To explore the function of Id3 in
lymphopoiesis, we first compared the total number of splenocytes and
thymocytes in 4- to 10-week-old Id3
/
mice
and their wild-type littermates. Id3
/
mice
contained normal numbers of splenocytes (Id3+/+,
7.5 × 107 ± 1.6 × 107;
Id3+/
, 6.4 × 107 ± 2.3 × 107; and Id3
/
,
6.9 × 107 ± 2.0 × 107;
n = 5) and thymocytes (Id3+/+,
24.3 × 107 ± 2.2 × 107;
Id3+/
, 25.8 × 107 ± 2.0 × 107; and Id3
/
,
23.0 × 107 ± 2.0 × 107;
n = 5). The B and T cells from spleen, lymph nodes,
thymus, and bone marrow were further analyzed by flow cytometry with a panel of lineage- and stage-specific markers (Fig.
2 and data not shown). Thymopoiesis in
Id3
/
mice was largely normal except for a
slight but consistent reduction in the proportion of CD4+
mature thymocytes (Id3+/+, 10.7% ± 1.2%;
Id3
/
, 6.5% ± 0.6%; n = 5;
P < 0.005) and CD8+ mature thymocytes
(Id3+/+, 4.7% ± 0.4%;
Id3
/
, 2.7% ± 0.5%; n = 5;
P < 0.005). However, the numbers and ratios of
CD4+ and CD8+ mature T cells in the spleens of
Id3
/
mice were normal. The numbers and
percentages of pro-B cells (B220+/CD43+) and
pre-B cells and immature B cells (B220+/CD43
)
in the bone marrow and mature B cells
(B220+/IgM+) in the spleen were normal for
Id3
/
mice (Fig. 2A). B cells from
Id3
/
mice expressed normal levels of major
histocompatibility complex (MHC) class II antigens (I-A) and CD23
surface molecules (Fig. 2B). Flow cytometry also detected the expected
numbers of B220+/CD5+ B1 cells in the
peritoneal cavity (Fig. 2A) and of myeloid cells in the bone marrow and
the spleen (data not shown). Id3
/
mice also
contained the normal frequency of follicular B cells (IgMlo
IgDhi) and marginal-zone B cells (IgMhi
CD21hi) (Fig. 2B). Hence, although Id3 is
expressed in most hematopoietic cell types, its function is either
dispensable or can be compensated by other Id genes during
myelopoiesis and lymphopoiesis.

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 2.
(A) T- and B-cell development in lymphoid tissues of
Id3 / mice. A three-color FACS analysis of
lymphocytes from the thymus, spleen, bone marrow, and peritoneal cavity
of Id3+/+ (left) and
Id3 / (right) mice is shown. Results are
representative of multiple tests and are shown as two-color dot plots
after eliminating the dead cells by 7AAD staining. The percentages of
relevant lymphocyte population are indicated in the quadrants. (B)
Surface marker expression and subpopulation of B cells in the spleens
of Id3 / mice. Splenocytes were isolated from
Id3+/+ (left) and
Id3 / (right) mice and examined by flow
cytometry analysis as described for panel A.
|
|
Aberrant Ig levels in serum in Id3 deficient mice.
Since Id3 but not Id1 and Id2 has been
reported to be highly expressed in mature B cells (43), we
set out to investigate whether a lack of Id3 has an impact
on humoral immunity. Ig levels in serum in naive
Id3
/
mice was determined by ELISA. While
basal levels of IgM, IgG2a, IgG2b, IgG3, and IgA in serum in
Id3
/
mice were comparable to those in
wild-type mice, the levels of IgG1 and IgG2a were reduced to 45% ± 8% and 57% ± 11% of wild-type levels, respectively (Fig.
3). This data suggests that although the
B and T cells in Id3
/
mice are
phenotypically normal, their function might be altered.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 3.
ELISA of Ig levels in serum of unimmunized
Id3+/+ (n = 16) and
Id3 / (n = 16) mice. Results
are presented as mean ± standard error for 16 mice for each
genotype. Asterisks denote values that are significantly different from
the wild-type controls (t test; P < 0.005).
|
|
Impaired humoral immune responses.
A role for Id3 in Ig
production has been indicated by its ability to repress class switching
in plasma cell lines (41). To further investigate the role
of Id3 in humoral immunity, we assessed the immune responses of
Id3 mice to several model antigens. When challenged i.p.
with DNP-KLH, Id3
/
mice were found to be
capable of producing normal levels of DNP-specific IgM, IgG1, IgG2b,
and IgA in both primary and secondary responses (Fig.
4). However, the ability of these mice to
produce DNP-specific IgG2a and IgG3 was 10-fold lower in the primary
response and 15-fold lower in the secondary response than for the
wild-type controls (Fig. 4A). When challenged with DNP-Ficoll,
Id3
/
mice displayed a 10-fold decrease of
DNP-specific IgM and IgA production in comparison to
Id3+/+ mice and no or near-basal levels of
DNP-specific IgG1, IgG2a, IgG2b, and IgG3 (Fig. 4B).
Id3
/
mice mounted a normal humoral response
to TNP-LPS, a TI-1 antigen (data not shown). These results define a
role for Id3 in some but not all classes of Ig isotype production.
Histological analysis of frozen tissue sections stained with peanut
agglutinin and IgM revealed normal germinal-center formation in mice
immunized with DNP-KLH and a normal distribution of antibody-forming
foci in mice immunized with DNP-Ficoll (data not shown). Therefore, the defects described above may not be explained by any malformation of the
splenic microenvironment.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 4.
(A) Humoral immune response to DNP-KLH.
Id3+/+ (n = 5) and
Id3 / mice (n = 5) mice were
injected i.p. with 100 µg of DNP-KLH in complete Freund's adjuvant
on day zero and were boosted without adjuvant 21 days later. The mice
were bled at the indicated times for ELISA of DNP-specific antibodies.
The relative concentrations of anti-DNP-specific antibody isotype are
shown as mean optical density (O.D.) and standard error. Serum dilution
factors are as follows: 1:1,000 for IgM and IgG1; 1:500 for IgG2a and
IgG3; 1:100 for IgG2b and IgA. Id3 / mice
show significantly reduced IgG2a and IgG3 production on days 14 and 28 (t test against wild-type controls; P < 0.005). (B) Humoral immune response to DNP-Ficoll. Mice were
injected i.p. with 25 µg of DNP-Ficoll on day zero and bled at the
indicated times. DNP-specific antibodies for six different isotypes
were analyzed by ELISA. Serum dilution factors are as follows: 1:1,000
for IgM and IgG3; 1:100 for the other four isotypes. A significant
difference between the two genotypes was found in all cases following
immunization (t test against wild type controls,
n = 5 for each genotype; P < 0.005).
|
|
Normal activation response to the BCR signal.
A normal B-cell
response to a foreign antigen entails two major steps: first, B-cell
activation by signals from the B-cell receptor (BCR), and second, cell
proliferation and/or differentiation. The abnormal humoral immune
responses observed in Id3
/
mice could
therefore result from a defect in either the first step or the second
step. To distinguish between these two possibilities, we first tested
the ability of Id3
/
mouse B cells to elicit
a calcium response to either anti-CD19 or F(ab')2 fragment
of anti-IgM antibodies. No differences in [Ca2+]i between wild-type and
Id3
/
mouse B cells were observed when the
splenic B cells were stimulated by suboptimal (10 µg/ml) or optimal
(40 µg/ml) concentrations of anti-IgM antibodies (Fig.
5A). A similar conclusion was reached when optimal concentrations (70 µg/ml) of anti-CD19 antibodies were
used (Fig. 5A). This analysis confirms that the BCR complex on
Id3
/
B cells is capable of receiving and
delivering signals.


View larger version (83K):
[in this window]
[in a new window]
|
FIG. 5.
(A) Splenocytes were stained with FITC-labeled anti-B220
monoclonal antibody after being loaded with Indo-1AM. B220+
B cells were examined for [Ca2+]i following
stimulation (indicated by arrows) with rabbit anti-mouse CD19 or
F(ab')2 goat anti-mouse IgM.
[Ca2+]i was determined as the ratio of Indo-1
fluorescence at 405 nm to 525 nm. The results are representative of
three pairs of Id3+/+ and
Id3 / mice. (B) Expression levels of MHC
class II antigen (Ia) in splenic B cells purified from
Id3+/+ (top) and Id3 /
(bottom) mice after a 24-h culture in the absence (dashed lines) or
presence (solid lines) of 10 µg of F(ab')2 goat
anti-mouse IgM per ml.
|
|
In addition to the calcium influx, full activation of a B cell is
characterized by up regulation of specific surface markers
including
MHC class II, CD19 (
9), CD44 (
62), and CD69
(
61).
These markers were expressed at normal levels in
Id3
/
mouse B cells and further up regulated
upon 24-h stimulation
with anti-IgM antibodies or LPS (Fig.
5B and data
not shown).
The level of increase for each marker was comparable to
that in
the wild-type controls. Therefore, we tentatively concluded
that
the impaired humoral immune responses in
Id3
/
mice are not due to a general defect in
the BCR pathway leading
to B-cell
activation.
Defective proliferation of Id3
/
mouse B
cells upon surface BCR cross-linking.
We next investigated the
proliferation status of Id3
/
mouse B cells
in tissue culture. It has been well documented that B-cell proliferation can be triggered by BCR and other divergent signaling cascades. To evaluate the effect of Id3 disruption on
various signaling events, purified splenic B cells from
Id3
/
and wild-type mice were stimulated with
a number of reagents. Id3
/
and
Id3+/+ mouse B cells gave similar proliferative
responses when treated with various concentrations of LPS, anti-CD38,
and anti-CD40 (Fig. 6A and data not
shown). PMA and ionomycin, which activate B cells through a protein
kinase C signaling pathway, also triggered a vigorous proliferation
response in both Id3
/
and
Id3+/+ mouse B cells (data not shown). In
contrast, the proliferation response of Id3
/
mouse B cells to the soluble F(ab')2 fragments of anti-IgM
was significantly lower than that of wild-type mouse B cells (34% ± 10% at 10 µg/ml [P < 0.005]; 23% ± 8% at 20 µg/ml [P < 0.005]) (Fig. 6A). No significant
difference was found in proliferation kinetics (assayed at 12-h
intervals over a 72-h period) between Id3
/
and Id3+/+ mouse B cells, ruling out the
possibility that the reduced 3H incorporation is due to
changes in the kinetics of the maximal proliferation response (data not
shown). The apoptotic rates determined by propidium iodide staining
were also similar for Id3
/
mouse B cells and
Id3+/+ mouse B cells treated with various
stimuli (data not shown). Finally, this defect could be corrected when
both IL-4 and anti-IgM were included in the B-cell culture (Fig. 6A).
Carboxyfluorescein diacetate succinimidyl ester (CFSE) treatment also
exerted a similar effect on Id3
/
mouse B
cells to that of IL-4 (data not shown). Because CFSE covalently binds
to many cellular proteins, we cannot distinguish if IL-4 or other
signaling pathways are altered by CFSE modification. Taken together,
these assays define a restricted role for Id3 downstream of
the BCR signal and necessary for B-cell proliferation. This function of
Id3 may be partially responsible for the impaired immune
response of Id3
/
mice to the TI-2 antigen.


View larger version (31K):
[in this window]
[in a new window]
|
FIG. 6.
(A) B-cell proliferation induced by the
F(ab')2 fragment of goat anti-mouse IgM at three different
concentrations (right) and by LPS (50 µg/ml), anti-CD40 monoclonal
antibody (10 µg/ml), and 100 U of IL-4 per ml plus 5 µg of
F(ab')2 fragment of goat anti-mouse IgM per ml (left).
Purified splenic B cells were cultured in the presence of the indicated
stimuli for 64 h, with [3H]thymidine being added
during the last 16 h. [3H]thymidine incorporation is
shown as the mean and standard error of triplicate cultures. Results
are representative of four independent experiments. (B) T-cell
proliferation induced by anti-CD3 (10 µg/ml), ConA (2 µg/ml), and
PMA (20 ng/ml) plus ionomycin (1 µg/ml) (P+I). Purified splenic T
cells were cultured for 54 h, with [3H]thymidine
being added during the last 16 h. Results are shown as in panel A
and are representative of four independent experiments.
|
|
BCR cross-linking leads to rapid up regulation of Id3.
Id3 has been identified as an immediate-early gene induced
by serum stimulation in fibroblasts (11, 35) and PMA
stimulation in human B cells (18). The defect in BCR-induced
B-cell proliferation in Id3-deficient B cells suggests that
Id3 may also be directly regulated by the BCR signal. To
test this hypothesis, we set out to determine the expression pattern of
Id3 in the early phase of B-cell proliferation upon surface
IgM stimulation. Purified splenic B cells were treated with the
soluble F(ab')2 fragments of anti-IgM, and total cellular
RNA was isolated after various times. An RT-PCR assay revealed that
there was a rapid induction of the level of Id3 by twofold
in the first 1.5 h of anti-IgM stimulation (Fig.
7). However, its expression pattern is
distinct from that of c-myc, a well-demonstrated
BCR-inducible early gene (34). While c-myc was
found to be induced fivefold in the first 1.5 h but sharply down
regulated to the basal level in 4 h, the level of Id3
went up threefold in 4 h. The expression level of the E2A gene
remained constant, which is consistent with the previous observation
that the levels of E proteins stayed unchanged during the transition
from the G0 to S phase of the cell cycle (28, 36). The expression kinetics for the c-myc and E2A
genes in Id3-deficient mouse B cells were identical to those
in wild-type mouse B cells, indicating that these two genes are not
directly affected by Id3 disruption. Finally, we found that
Id3 was also induced by LPS treatment of purified B cells
(data not shown).

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 7.
Induction of Id3 expression in purified
splenic B cells stimulated with anti-IgM. RNA was isolated from the
wild-type and Id3 / mouse B cells stimulated
with anti-IgM for the indicated times (0, 1.5, and 4 h). The
expression of Id3, E2A, c-myc, and
EF1 was determined by the RT-PCR assay with gene-specific
primers. Each primer pair was tested for linear PCR amplification by
running incremental PCR cycles. Results shown are the optimal cycle
conditions for the given genes. Quantitation was further confirmed by
repeating the entire proliferation and RNA analysis by using B-cells
purified from a separate batch of animals.
|
|
Enhanced in vitro differentiation abilities of
Id3
/
mouse B cells.
The
differentiation ability of Id3
/
mouse B
cells was assessed by culturing purified B cells under
isotype-switching conditions. Id3
/
mouse B
cells secreted five times more IgM than did wild-type mouse B cells
when stimulated with LPS and a significantly larger amount of IgG1 (2.5 times larger with 200 U of IL-4 per ml and 1.6 times higher with 1,000 U of IL-4 per ml) when stimulated with LPS and IL-4 (Fig.
8). This result indicates a negative role for Id3 in regulating differentiation and isotype switching.
Because the antibody production in Id3
/
mice
is reduced rather than enhanced, one must consider that Id3
disruption may also affect other cell types important for humoral
immunity.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 8.
Ig secretion in stimulated splenic B cells. B cells from
Id3+/+ and Id3 / mice
were purified from spleens and cultured for 6 days in the presence of
various stimuli as indicated in the figure. The concentrations of Ig
isotypes in the culture supernatants were determined by ELISA. Similar
results were obtained from four independent experiments.
|
|
Reduced expression of gamma interferon in anti-CD3-stimulated
Id3
/
mouse T cells.
Given the
important role of T-cells in isotype switching and overall humoral
immunity, we asked if T-cell function is compromised by Id3
disruption. Proliferation assays were carried out with purified T cells
from spleen and lymph nodes. No noticeable difference between
Id3
/
and wild-type mouse T cells was
observed when cells were stimulated with anti-CD3, anti-CD3 plus
anti-CD28, ConA, or PMA plus ionomycin over a range of concentrations
(Fig. 6C and data not shown). In addition,
Id3
/
mouse T cells displayed normal levels
of surface CD25, CD44, and CD69 before and after stimulation compared
with Id3+/+ mouse T cells. These assays
demonstrate that Id3 is not required for T-cell activation
and proliferation under these defined conditions. However, RNA analysis
of cytokine gene expression in anti-CD3-stimulated primary splenocyte
culture revealed a 33% ± 6% reduction of gamma interferon (INF-
)
mRNA in the Id3
/
mouse T-cell samples (Fig.
9). The expression of other cytokine genes shown in the figure was relatively normal (longer exposure [data
not shown]). This result suggests that Id3
/
mouse T cells might also contribute to the impaired humoral immune responses seen in vivo.

View larger version (97K):
[in this window]
[in a new window]
|
FIG. 9.
Cytokine gene expression in anti-CD3-stimulated
Id3 / mouse splenocytes. Erythrocyte-depleted
splenocytes from Id3+/+ and
Id3 / mice were cultured with anti-CD3 for
48 h. Total RNAs were prepared, and cytokine gene expression was
determined by an RNase protection assay. The identity of each band is
indicated on the right. L32 and GAPDH are controls for mRNA quantity
and quality.
|
|
Rescue of the proliferation defect of
Id3
/
mouse B cells by overexpression of the
Id1 gene.
Given the presumed functional relationship between Id3
and E2A proteins, we propose that the proliferation defect of
Id3
/
mouse B cells may be due to
dysregulation of E2A function. E2A can inhibit cell cycle progression
by several hypothetical mechanisms including a direct transcriptional
activation of p21, a CDK inhibitor (47). Deletion of
Id3 may leave the E2A protein level unchecked and thus cause
cell cycle arrest at G1 phase. To experimentally address
this functional link between E2A and Id3, we attempted to rescue
Id3 deficiency with a B-cell-specific Id1
transgene. Id1 and Id3 proteins have 69% sequence homology in their
HLH domains (11). Both of these proteins are capable of
antagonizing the DNA-binding activity of E2A proteins (11,
32). It has been shown that mice carrying an Id1
transgene under the mb-1 promoter (Id1tg)
display a severe block in early B-cell development and a reduced number
of mature B cells (59). Nonetheless, these
Id1tg mature B cells are phenotypically
indistinguishable from the wild-type B cells judged by expression
patterns of B-cell markers including B220, CD19, mIgM, mIgD, CD44,
CD69, CD23, and Ia in the resting and activated states
(data not shown). Introduction of this Id1 transgene into
the Id3
/
background results in a severe
reduction of B-cell numbers in the bone marrow, a phenotype identical
to that of the Id1tg mice, but close to normal
numbers of B220+ IgM+ mature B cells in the
spleen (Fig. 10A and data not shown).
Although the exact functional relationship between the Id1
transgene and the Id3 gene requires further investigation,
the result of this simple cross indicates a functional compensation
between the Id1 transgene and the endogenous Id3
gene in maintaining the splenic B-cell numbers.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 10.
(A) FACS analysis of bone marrow and splenic B cells
from Id3+/+ (top) Id1tg
(middle), and Id3 /
Id1tg (bottom) mice. The percentage of
B220+/IgM+ cells is shown in the top right
quadrant of each dot plot. (B) Comparison of
Id3+/ , Id3+/
Id1tg, Id3 / , and
Id3 / Id1tg mouse
splenic B cells for their proliferative response to the
F(ab')2 fragment of anti-IgM (20 µg/ml), IgM (5 µg/ml)
plus IL-4 (100 U), or LPS (100 µg/ml). [3H]thymidine
incorporation is shown as mean and standard error of a triplicate
culture. Results are representative of three independent experiments.
|
|
B cells purified from spleens of
Id3+/+,
Id3
/
,
Id3+/
Id1tg, and
Id3
/
Id1tg mice were analyzed for their proliferation
responses to LPS,
IgM, or IgM plus IL-4. As shown in Fig.
10B,
Id3+/
Id1tg mouse B
cells, which resemble
Id1tg mouse B cells (data
not shown), proliferate in a similar manner
to that of
Id3+/+ mouse B cells. The proliferation rate of
Id3
/
Id1tg mouse B
cells in response to anti-IgM stimulation was much higher
than that of
Id3
/
mouse B cells and even slightly (but
reproducibly) higher than
that of wild-type mouse B cells. Thus, the
function of
Id3 in
supporting B-cell proliferation can be
replaced by the ectopically
expressed
Id1 gene. This result
supports the notion that a minimal
level of Id proteins is needed to
antagonize a bHLH protein dimer
(most probably involving E2A proteins)
which negatively regulates
cell cycle
progression.
 |
DISCUSSION |
In this study we generated Id3-deficient mice and
identified a novel role of Id3 in humoral immunity. Despite
the ubiquitous expression pattern and presumed function of
Id3 in multiple cell types, mice lacking the Id3
gene appear viable and fertile and exhibit normal activity. Although no
abnormality is observed in lymphoid development,
Id3
/
mice show selective defects in humoral
immunity. This phenotype is partially explained by the study of
purified B cells, which shows that Id3 is required for
BCR-mediated B-cell proliferation, and by the study of
Id3
/
mouse T cells, which shows that
Id3 is required for optimal expression of IFN-
. Finally,
the rescue of the Id3-deficient phenotype by an
Id1 transgene suggests one possible mechanism: the role of Id3 is to relieve the cell cycle-inhibitory effect imposed
by E2A or E2A-like bHLH molecules.
Id3 is required for an optimal humoral immune response.
Id3
/
mice fail to mount a proper immune
response to DNP-Ficoll, a TI-2 antigen. Ti-2 antigens are classified as
antigens that stimulate antibody production in the absence of MHC class
II-restricted T-cell help (43). Although the molecular basis
of TI-2 immunity is not clear, our present study supports the notion
that Id3 may respond to the BCR signal and allow B cells to
proliferate. It is also possible, however, that the development of
DNP-Ficoll-specific B cells is impaired in naive
Id3
/
mice, which then leads to a weaken
response. Further tests of other TI-2 antigens and a detailed
characterization of the Id3 expression pattern in the
marginal zone, where the TI-2 immune response is thought to occur
(43), may help resolve this issue.
The immune response to TD antigens is also partially impaired in
Id3
/
mice. It has been established that a
full TD response requires
a proper interaction between the
antigen-specific B cells and
T cells. The reduction of IgG2a and IgG3
levels observed in the
TD response of
Id3
/
mice may be attributed to a specific rather than general defect
in T
cells, since other Ig isotypes are produced at normal levels
and
cultured
Id3
/
mouse T cells respond properly
to various stimuli including anti-CD3,
anti-CD3 plus anti-CD28, PMA
plus ionomycin, and ConA. This defect
may reflect an impaired ability
of
Id3
/
mouse helper T cells to produce
certain cytokines required for
class switching or a defect in
Id3
/
mouse B cells in responding to the
switch signals. The underlying
mechanism, involving either the T cell
or the B cell, must represent
a very restricted function of
Id3, since only IgG2a and IgG3 but
not other Ig isotypes are
affected by the gene deficiency. Indeed,
we observed a small but
consistent reduction in the expression
level of IFN-

in anti-CD3
treated T cells. IFN-

, a Th1 cytokine,
induces germ line

2a
transcripts and subsequent switching to
IgG2a in mouse B cells
(
15,
53,
56). IFN-

also induces
germ line

3
transcripts and switching to IgG3 in B cells activated
with
dextran-conjugated anti-IgD antibodies plus IL-5 (
69).
This
small reduction of IFN-

revealed in the culture assay could
be
amplified in the time course of immunization. However, this
result and
explanation do not preclude other possible mechanisms.
The analysis
carried out in this study only provides an assessment
of certain
aspects of
Id3 function. It is highly possible that
other
defects associated with
Id3
/
mouse T cells
or other cell types also contribute to the impaired
immune responses in
Id3
/
mice.
Id3 and isotype switching.
B cells can change
their CH portion of the expressed heavy chain through
heavy-chain class switch recombination (12, 24). This
process occurs during immunization with either TI or TD antigens (25, 43). Several lines of evidence have suggested that bHLH and Id proteins regulate class switching. Id3 has been
suggested to regulate Ig heavy-chain 3' enhancer activity via the E5
site, a functionally important E12/E47 binding site (41).
The Ig heavy-chain 3' enhancer is activated in the late stage of B-cell
development and is possibly involved in class switch recombination
(13). Overexpression of Id3 repressed the Ig heavy-chain 3'
enhancer in plasma cells by abrogating the DNA-binding ability of
E12/E47 (41). In addition, the involvement of bHLH proteins
in isotype switching is supported by the finding that E47 or a highly
related bHLH protein is part of the SNAP complex, which binds to an
E2-box-like site in the S
switch regions (37). Our
isotype-switching assay with isolated B-cells indicates a negative role
for Id3 in isotype switching and suggests that an
interaction between E2A and Id3 proteins may be critical in regulating
class switching. However, this result from purified B cells is opposite
of the impaired humoral immunity observed in
Id3
/
mice. The apparent discrepancy between
the in vitro and in vivo results may be explained by the following
possibilities: (i) Id3 may be required for clonal expansion
of certain activated B cells, and therefore deletion of Id3
may lead to a reduced Ig production; and (ii) Id3 may be
involved in regulating cytokine gene expression, which ultimately
controls Ig class switching and production. In the course of an immune
response to antigens, both events may contribute to isotype switching
and the final outcome of humoral immunity.
Id3 is exclusively required for BCR-mediated B-cell
proliferation.
B cells can be activated through different
signaling pathways. To ensure proper humoral immunity, B cells must be
able to differentiate and integrate different signaling events and give rise to the appropriate biological responses. While the signaling events occurring at and immediately downstream of the BCR level have
been heavily investigated, little is known about how the signals are
interpreted by nuclear factors which directly control differentiation
and/or proliferation. Id3, as an immediate-early response
gene, has a transient peak expression in human B cells after mitogen
treatment (18). It has been suggested, but not proved, that
the transient expression of Id3 in many cells including B
cells promotes cell proliferation. We show in this study that Id3
/
is dispensable in B-cell proliferation
responses to LPS, CD40, or IgM plus IL-4, which represent several
signaling pathways. In addition, no overt abnormalities are observed in
the development of Id3
/
B cells, during
which extensive cell proliferation must occur. These results indicate
that Id3 may not be a common factor linked to cell cycle
progression or that its function may be compensated by other
coexpressed Id genes.
On the other hand,
Id3 is clearly required for B-cell
proliferation when B cells are stimulated by BCR cross-linking. This
result indicates that the function of
Id3 must be within the
BCR
signaling pathway and before the multipathway converging point
leading to the cell cycle progression. A possible target of Id3
is E2A,
which has been shown in NIH 3T3 cells to cause a growth
arrest by
activating p21 expression (
47). It has been reported
that
during the early G
1 phase of the cell cycle, the
E-box-binding
activities of E2A proteins are transiently depressed at a
time
coincident with the peak induction of Id proteins (
28,
36).
Therefore, up regulation of
Id3 may directly
exert a negative
effect on the E2A activity and consequently on p21
activity. The
activity of E2A can be further regulated by other Id
molecules,
by ABF-1 (a recently identified bHLH factor exclusively
expressed
in activated B cells [
38]), or by its own
transcription and
posttranslational modification (
5,
54,
70). We propose
that either E2A or the downstream target of E2A
could function
as one converging point that leads several signaling
pathways
to the cell cycle machinery. Among many cell cycle regulators,
p27 has been indicated as an important CDK inhibitor in regulating
B-cell proliferation induced by BCR and IL-4 costimulation (
8,
57). We have attempted to determine which cell cycle component
is
altered in
Id3-deficient B cells upon BCR cross-linking.
Thus
far, no prominent candidate has been identified by Western
analysis
of CDK inhibitors including p15, p16, p18, p19, p21, and p27
(unpublished
data). Clearly, additional tests including genetic
approaches,
may be needed before one can firmly establish a causative
link
between
Id3 and cell cycle
regulation.
Id1 is capable of replacing Id3
function.
A functional rescue of Id3 by Id1
supports the notion that E2A is the common target of all Id proteins
and that its presence controls cell cycle progression. However, the
mechanism underlying the functional rescue is obscured by the following
facts: First, the Id1 transgene is expressed from the mb-1
promoter, which may not be regulated in the same way as the endogenous
Id3 gene during the BCR signaling event. Second, the Id1
protein lacks the CDK consensus site (28) present on Id2 and
Id3, and thus its activity may be differentially regulated during the
cell cycle (4, 29). Therefore, how the Id1
transgene senses the BCR signal is not clear. One plausible explanation
is that a constitutive high-level expression of Id1 may
reduce the level of functional E2A proteins. Consequently, the signal
threshold required for overcoming the G1 block imposed by
E2A proteins is lowered. In other words, the Id1 transgene
makes B cells more sensitive to proliferation signals. Another
possibility is that both Id3 and Id1 are
regulated by the BCR signal at the posttranslational level
through a mechanism yet to be identified. Therefore, a bigger issue
raised by the Id1 rescue experiment is that perhaps
Id3 is regulated by BCR signal at multiple levels including
transcription and posttranslational modification.
Id3 and early B-cell development.
E2A is a key
regulatory gene in B-cell development (3, 72). The numbers
of pro- and pre-B cells produced in the bone marrow are tightly
correlated with the dosage of E2A proteins (2, 72), which in
turn can be modulated by several other E proteins and Id proteins
(18, 70). It has been generally accepted that the role of
Id genes is to negatively regulate E2A activity during
B-cell differentiation. We anticipated that deletion of Id3
could conceivably perturb E2A activity by changing the balance of the
protein dimers. However, no abnormality in B-cell development is
observed in Id3
/
mice. To further evaluate
the activity of Id3 in B-cell development, we generated E2A
Id3 double-mutant mice by combining the Id3
mutation with various E2A mutant alleles including E12ko
and E47bm, two hypomorph E2A alleles (70).
Although E2A-deficient mice do not make any B cells, E12ko
and E47bm mice are capable of producing a limited number of
B cells in the neonatal stage (70). If Id3 can
modulate the activity of E12 or E47, we expect to see an increase of
B-cell numbers in the E12ko or E47bm mice after
disruption of Id3. Again, analysis of Id3 and E12 or E47 double-mutant mice failed to show any effect of Id3
deficiency on B-cell development. In conclusion, the defect imposed by
the E2A mutations cannot be relieved by deletion of Id3
(data not shown). This result raises the possibility that
Id3 does not play a major role in early B-cell development
owing to either its expression level being insufficient or its protein
being inactive. This view is supported by the fact that Id3
knockout also fails to rescue the bone marrow B-cell development
imposed by the Id1 transgene. Alternatively, function of
Id3 in B-cell development may be compensated by other
Id genes expressed in the B-cell lineage. A similar argument has been made in the study of Id1 gene-deficient mice.
Disruption of Id1 also failed to show any detectable
contribution to B-cell development when tested either alone or in
combination with E2A deficiency (68). With both
Id3- and Id1-deficient mice available now,
generation and analysis of Id1 and Id3 doubly
deficient mice will help to resolve the compensatory roles of Id
proteins in the development of B cells and many other cell types.
 |
ACKNOWLEDGMENTS |
We thank Peifeng Cheng for assistance in isolating Id3
cDNA and genomic DNA, Thomas Tedder and Makoto Inoaki for providing reagents and technical advice on immune system assays, Mike Cook for
assistance in the calcium influx assay, Meifang Dai for assistance in
mouse work, Dawn Phelp and Yue Xiong for assistance in
coimmunoprecipitation Western analysis of cell cycle proteins, and
Douglas Steeber for critical reading of the manuscript.
This work has been supported by the Leukemia Society of America, the
Whitehead Scholarship, and NCI grant (R01 CA72433-01) to Y.Z.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Immunology, Box 3010, Jones Bldg. 329, Research Dr., Duke University Medical Center, Durham, NC 27710. Phone: (919) 613-7824. Fax: (919)
684-8982. E-mail: yzhuang{at}acpub.duke.edu.
Present address: Department of Dermatology, School of Medicine,
Kanazawa University, Kanazawa 920, Ishikawa, Japan.
 |
REFERENCES |
| 1.
|
Atherton, G. T.,
H. Travers,
R. Deed, and J. D. Norton.
1996.
Regulation of cell differentiation in C2C12 myoblasts by the Id3 helix-loop-helix protein.
Cell Growth Differ.
7:1059-1066[Abstract].
|
| 2.
|
Bain, G.,
E. C. Robanus Maandag,
H. P. te Riele,
A. J. Feeney,
A. Sheehy,
M. Schlissel,
S. A. Shinton,
R. R. Hardy, and C. Murre.
1997.
Both E12 and E47 allow commitment to the B cell lineage.
Immunity
6:145-154[Medline].
|
| 3.
|
Bain, G.,
E. C. Maandag,
D. J. Izon,
D. Amsen,
A. M. Kruisbeek,
B. C. Weintraub,
I. Krop,
M. S. Schlissel,
A. J. Feeney,
M. van Roon,
M. van der Valk,
H. P. J. te Riele,
A. Berns, and C. Murre.
1994.
E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements.
Cell
79:885-892[Medline].
|
| 4.
|
Barone, M. V.,
R. Pepperkok,
F. A. Peverali, and L. Philipson.
1994.
Id proteins control growth induction in mammalian cells.
Proc. Natl. Acad. Sci. USA
91:4985-4988[Abstract/Free Full Text].
|
| 5.
|
Benezra, R.
1994.
An intermolecular disulfide bond stabilizes E2A homodimers and is required for DNA binding at physiological temperatures.
Cell
79:1057-1067[Medline].
|
| 6.
|
Benezra, R.,
R. L. Davis,
D. Lockshon,
D. L. Turner, and H. Weintraub.
1990.
The protein Id: a negative regulator of helix-loop-helix DNA binding proteins.
Cell
61:49-59[Medline].
|
| 7.
|
Biggs, J.,
E. V. Murphy, and M. A. Israel.
1992.
A human Id-like helix-loop-helix protein expressed during early development.
Proc. Natl. Acad. Sci. USA
89:1512-1516[Abstract/Free Full Text].
|
| 8.
|
Blanchard, D. A.,
M. T. Affredou, and A. Vazquez.
1997.
Modulation of the p27kip1 cyclin-dependent kinase inhibitor expression during IL-4 mediated human B cell activation.
J. Immunol.
158:3054-3061[Abstract].
|
| 9.
|
Carter, R. H., and D. T. Fearon.
1992.
CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes.
Science
256:105-107[Abstract/Free Full Text].
|
| 10.
|
Choi, J. K.,
C. P. Shen,
H. S. Radomska,
L. A. Eckhardt, and T. Kadesch.
1997.
E47 activates the Ig-heavy chain and TdT loci in non-B cells.
EMBO J.
15:5014-5021[Medline].
|
| 11.
|
Christy, B. A.,
L. K. Sanders,
L. F. Lau,
N. G. Copeland,
N. A. Jenkins, and D. Nathans.
1991.
An Id-related helix-loop-helix protein encoded by a growth factor-inducible gene.
Proc. Natl. Acad. Sci. USA
88:1815-1819[Abstract/Free Full Text].
|
| 12.
|
Coffman, R. L.,
D. A. Lebman, and P. Rothman.
1993.
Mechanism and regulation of immunoglobulin isotype switching.
Adv. Immunol.
54:229-270[Medline].
|
| 13.
|
Cogne, M.,
R. Lansford,
A. Bottaro,
J. Zhang,
J. Gorman,
F. Young,
H. L. Cheng, and F. W. Alt.
1994.
A class switch control region at the 3' end of the immunoglobulin heavy chain locus.
Cell
77:737-747[Medline].
|
| 14.
|
Coligan, J. E.,
A. M. Kruisbeek,
D. H. Margulies,
E. M. Shevach, and W. Strober (ed.).
1990.
Current protocols in immunology, p. 5.51-5.53.
Wiley Interscience, New York, N.Y.
|
| 15.
|
Collins, J. T., and W. A. Dunnick.
1993.
Germline transcripts of the murine immunoglobulin gamma 2a gene: structure and induction by IFN-gamma.
Int. Immunol.
5:885-891[Abstract/Free Full Text].
|
| 16.
|
Datto, M. B.,
J. P. Frederick,
L. Pan,
A. J. Borton,
Y. Zhuang, and X. F. Wang.
1999.
Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction.
Mol Cell. Biol.
19:2495-2504[Abstract/Free Full Text].
|
| 17.
|
Deed, R. W.,
S. M. Bianchi,
G. T. Atherton,
D. Johnston,
M. Santibanez-Koref,
J. J. Murphy, and J. D. Norton.
1993.
An immediate early human gene encodes an Id-like helix-loop-helix protein and is regulated by protein kinase C activation in diverse cell types.
Oncogene
8:599-607[Medline].
|
| 18.
|
Deed, R. W.,
E. Hara,
G. T. Atherton,
G. Peters, and J. D. Norton.
1997.
Regulation of Id3 cell cycle function by Cdk-2-dependent phosphorylation.
Mol. Cell. Biol.
17:6815-6821[Abstract].
|
| 19.
|
Desprez, P. Y.,
E. Hara,
M. J. Bissell, and J. Campisi.
1995.
Suppression of mammary epithelial cell differentiation by the helix-loop-helix protein Id-1.
Mol. Cell. Biol.
15:3398-3404[Abstract].
|
| 20.
|
Edmondson, D. G., and E. N. Olson.
1993.
Helix-loop-helix proteins as regulators of muscle-specific transcription.
J. Biol. Chem.
268:755-758[Free Full Text].
|
| 21.
|
Ellis, H. M.,
D. R. Spann, and J. W. Posakony.
1990.
Extramacrochaetae, a negative regulator of sensory organ development in Drosophila, defines a new class of helix-loop-helix proteins.
Cell
61:27-38[Medline].
|
| 22.
|
Ellmeier, W.,
A. Aguzzi,
E. Kleiner,
R. Kurzbauer, and A. Weith.
1992.
Mutually exclusive expression of a helix-loop-helix gene and N-myc in human neuroblastomas and in normal development.
EMBO J.
11:2563-2571[Medline].
|
| 23.
|
Engel, P.,
L.-J. Zhou,
D. C. Ord,
S. Sato,
B. Koller, and T. F. Tedder.
1995.
Abnormal B lymphocyte development, activation and differentiation in mice that lack or overexpress the CD19 signal transduction molecule.
Immunity
3:39-50[Medline].
|
| 24.
|
Esser, C., and A. Radbruch.
1990.
Immunoglobulin class switching: molecular and cellular analysis.
Annu. Rev. Immunol.
8:717-735[Medline].
|
| 25.
|
Finkelman, F. D.,
J. Holmes,
I. M. Katona,
J. F. Jr. Urban,
M. P. Beckmann,
L. S. Park,
K. A. Schooley,
R. L. Coffman,
T. R. Mosmann, and W. E. Paul.
1990.
Lymphokine control of in vivo immunoglobulin isotype selection.
Annu. Rev. Immunol.
8:303-333[Medline].
|
| 26.
|
Garrell, J., and J. Modolell.
1990.
The Drosophila extramacrochaetae locus, an antagonist of proneural genes that, like these genes, encodes a helix-loop-helix protein.
Cell
61:39-48[Medline].
|
| 27.
|
Goldfarb, A. N.,
J. P. Flores, and K. Lewandowska.
1997.
Involvement of the E2A basic helix-loop-helix protein in immunoglobulin heavy chain class switching.
Mol. Immunol.
33:947-956.
|
| 28.
|
Hara, E.,
M. Hall, and G. Peters.
1997.
Cdk2-dependent phosphorylation of Id2 modulates activity of E2A-related transcription factors.
EMBO J.
16:332-342[Medline].
|
| 29.
|
Hara, E.,
T. Yamaguchi,
H. Nojima,
T. Ide,
J. Campisi,
H. Okayama, and K. Oda.
1994.
Id-related genes encoding helix-loop-helix proteins are required for G1 progression and are repressed in senescent human fibroblasts.
J. Biol. Chem.
269:2139-2145[Abstract/Free Full Text].
|
| 30.
|
Heemskerk, M. H.,
B. Blom,
G. Nolan,
A. P. Stegmann,
A. Q. Bakker,
K. Weijer,
P. C. Res, and H. Spits.
1998.
Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3.
J. Exp. Med.
186:1597-1602[Abstract/Free Full Text].
|
| 31.
|
Jan, Y. N., and L. Y. Jan.
1993.
HLH proteins, fly neurogenesis, and vertebrate myogenesis.
Cell
75:827-830[Medline].
|
| 32.
|
Jen, Y.,
H. Weintraub, and R. Benezra.
1992.
Overexpression of Id protein inhibits the muscle differentiation program: in vivo association of Id with E2A proteins.
Genes Dev.
6:1466-1479[Abstract/Free Full Text].
|
| 33.
|
Johnson, J. E.,
S. J. Birren, and D. J. Anderson.
1990.
Two rat homologues of Drosophila achaete-scute specifically expressed in neuronal precursors.
Nature
346:858-861[Medline].
|
| 34.
|
Kelly, K.,
B. H. Cochran,
C. D. Stiles, and P. Leder.
1983.
Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor.
Cell
35:603-610[Medline].
|
| 35.
|
Lau, L. F., and D. Nathans.
1987.
Expression of a set of growth-related immediate early genes in BALB/c 3T3 cells: coordinate regulation with c-fos or c-myc.
Proc. Natl. Acad. Sci. USA
84:1182-1186[Abstract/Free Full Text].
|
| 36.
|
Loveys, D. A.,
M. B. Streiff, and G. I. Kato.
1996.
E2A basic-helix-loop-Helix transcription factors are negatively regulated by serum growth factors and by the Id3 proteins.
Nucleic Acids Res.
24:2813-2820[Abstract/Free Full Text].
|
| 37.
|
Ma, L.,
B. Hu, and A. L. Kenter.
1997.
Ig S gamma-specific DNA binding protein SNAP is related to the helix-loop-helix transcription factor E47.
Int. Immunol.
9:1021-1029[Abstract/Free Full Text].
|
| 38.
|
Massari, M. E.,
R. R. Rivera,
J. R. Voland,
M. W. Quong,
T. M. Breit,
J. J. M. van Dongen,
O. D. de Smit, and C. Murre.
1998.
Characterization of ABF-1, a novel basic helix-loop-helix transcription factor expressed in activated B lymphocytes.
Mol. Cell. Biol.
18:3130-3139[Abstract/Free Full Text].
|
| 39.
|
Mellentin, J. D.,
S. D. Smith, and M. L. Cleary.
1989.
Lyl-1, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif.
Cell
58:77-83[Medline].
|
| 40.
|
Melnikova, I. N., and B. A. Christy.
1996.
Muscle cell differentiation is inhibited by the helix-loop-helix protein Id3.
Cell Growth Differ.
7:1067-1079[Abstract].
|
| 41.
|
Meyer, K. B.,
M. Skogberg,
C. Margenfeld,
J. Ireland, and S. Pettersson.
1995.
Repression of the immunoglobulin heavy chain 3' enhancer by helix-loop-helix protein Id3 via a functionally important E47/E12 binding site: implications for developmental control of enhancer function.
Eur. J. Immunol.
25:1770-1777[Medline].
|
| 42.
|
Moldes, M.,
F. Lasnier,
B. Feve,
J. Pairault, and P. Djian.
1997.
Id3 prevents differentiation of preadipose cells.
Mol. Cell. Biol.
17:1796-1804[Abstract].
|
| 43.
|
Mond, J. J.,
A. Lees, and C. M. Snapper.
1995.
T cell-independent antigens type 2.
Annu. Rev. Immunol.
13:655-692[Medline].
|
| 44.
|
Murphy, J. J., and J. D. Norton.
1990.
Cell-type-specific early response gene expression during plasmacytoid differentiation of human B lymphocytic leukemia cells.
Biochim. Biophys. Acta
1049:261-271[Medline].
|
| 45.
|
Murre, C.,
P. S. McCaw, and D. Baltimore.
1989.
A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins.
Cell
56:777-783[Medline].
|
| 46.
|
Murre, C.,
P. S. McCaw,
H. Vaessin,
M. Caudy,
L. Y. Jan,
Y. N. Jan,
C. V. Cabrera,
J. N. Buskin,
S. D. Hauschka,
A. B. Lassar,
H. Weintraub, and D. Baltimore.
1989.
Interactions between heterodimeric helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence.
Cell
58:537-544[Medline].
|
| 47.
|
Prabhu, S.,
A. Ignatova,
S. T. Park, and X. H. Sun.
1997.
Regulation of the expression of cyclin-dependent kinase inhibitor p21 by E2A and Id proteins.
Mol. Cell. Biol.
17:5888-5896[Abstract].
|
| 48.
|
Riechmann, V.,
I. van Cruchten, and F. Sablitzky.
1994.
The expression pattern of Id4, a novel dominant negative helix-loop-helix protein, is distinct from Id1, Id2 and Id3.
Nucleic Acids Res.
22:749-755[Abstract/Free Full Text].
|
| 49.
|
Roberts, V. J.,
R. Steenbergen, and C. Murre.
1993.
Localization of E2A mRNA expression in developing and adult rat tissues.
Proc. Natl. Acad. Sci. USA
90:7583-7587[Abstract/Free Full Text].
|
| 50.
|
Rupp, R. A., and H. Weintraub.
1991.
Ubiquitous MyoD transcription at the midblastula transition precedes induction-dependent MyoD expression in presumptive mesoderm of X. laevis.
Cell
65:927-937[Medline].
|
| 51.
|
Sato, S.,
N. Ono,
D. Steeber,
D. Pisetsky, and T. F. Tedder.
1996.
CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity.
J. Immunol.
157:4371-4378[Abstract].
|
| 52.
|
Schlissel, M.,
A. Voronova, and D. Baltimore.
1991.
Helix-loop-helix transcription factor E47 activates germ-line immunoglobulin heavy-chain gene transcription and rearrangement in a pre-T-cell line.
Genes Dev.
5:1367-1376[Abstract/Free Full Text].
|
| 53.
|
Severinson, E.,
C. Fernandez, and J. Stavnezer.
1990.
Induction of germ-line immunoglobulin heavy chain transcripts by mitogens and interleukins prior to switch recombination.
Eur. J. Immunol.
20:1079-1084[Medline].
|
| 54.
|
Shen, C.-P., and T. Kadesch.
1995.
B-cell-specific DNA binding by an E47 homodimer.
Mol. Cell. Biol.
15:4518-4524[Abstract].
|
| 55.
|
Shoji, W.,
T. Yamamoto, and M. Obinata.
1994.
The helix-loop-helix protein Id inhibits differentiation of murine erythroleukemia cells.
J. Biol. Chem.
269:5078-5084[Abstract/Free Full Text].
|
| 56.
|
Snapper, C. M., and W. E. Paul.
1987.
Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production.
Science
236:944-947[Abstract/Free Full Text].
|
| 57.
|
Solvason, N.,
W. W. Wu,
N. Kabra,
X. Wu,
E. Lees, and M. C. Howard.
1997.
Induction of cell cycle regulatory proteins in anti-immunoglobulin-stimutated mature B lymphocytes.
J. Exp. Med.
184:407-417[Abstract/Free Full Text].
|
| 58.
|
Stanton, L. W.,
P. D. Fahrlander,
P. M. Tesser, and K. B. Marcu.
1984.
Nucleotide sequence comparison of normal and translocated murine c-myc genes.
Nature
310:423-425[Medline].
|
| 59.
|
Sun, X. H.
1994.
Constitutive expression of the Id1 gene impairs mouse B cell development.
Cell
79:893-900[Medline].
|
| 60.
|
Sun, X. H.,
N. G. Copeland,
N. A. Jenkins, and D. Baltimore.
1991.
Id proteins Id1 and Id2 selectively inhibit DNA binding by one class of helix-loop-helix proteins.
Mol. Cell. Biol.
11:5603-5611[Abstract/Free Full Text].
|
| 61.
|
Swat, W.,
M. Dessing,
H. von Boehmer, and P. Kisielow.
1993.
CD69 expression during selection and maturation of CD4+8+ thymocytes.
Eur. J. Immunol.
23:739-746[Medline].
|
| 62.
|
Testi, R.,
J. H. Phillips, and L. L. Lanier.
1989.
Leu 23 induction as an early marker of functional CD3/T cell antigen receptor triggering. Requirement for receptor cross-linking, prolonged elevation of intracellular [Ca++] and stimulation of protein kinase C.
J. Immunol.
142:1854-1860[Abstract].
|
| 63.
|
Voronova, A., and D. Baltimore.
1990.
Mutations that disrupt DNA binding and dimer formation in the E47 helix-loop-helix protein map to distinct domains.
Proc. Natl. Acad. Sci. USA
87:4722-4726[Abstract/Free Full Text].
|
| 64.
|
Weintraub, H.
1993.
The MyoD family and myogenesis: redundancy, networks, and thresholds.
Cell
75:1241-1244[Medline].
|
| 65.
|
White, P. S.,
J. M. Maris,
C. Beltinger,
E. Sulman,
H. N. Marshall,
M. Fujimori,
B. A. Kaufman,
J. A. Biegel,
C. Allen,
C. Hilliard,
M. B. Valentine,
A. T. look,
H. Enomoto,
S. Sakiyama, and G. M. Brodeur.
1995.
A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3.
Proc. Natl. Acad. Sci. USA
92:5520-5524[Abstract/Free Full Text].
|
| 66.
|
Wilson, R. B.,
M. Kiledjian,
C. P. Shen,
R. Benezra,
P. Zwollo,
S. M. Dymecki,
S. V. Desiderio, and T. Kadesch.
1991.
Repression of immunoglobulin enhancers by the helix-loop-helix protein Id: implications for B-lymphoid-cell development.
Mol. Cell. Biol.
11:6185-6191[Abstract/Free Full Text].
|
| 67.
|
Xin, X. Q.,
C. Nelson,
L. Collins, and K. Dorshkind.
1994.
Kinetics of E2A basic helix-loop-helix-protein expression during myelopoiesis and primary B cell differentiation.
J. Immunol.
151:5398-5407[Abstract].
|
| 68.
|
Yan, W.,
A. Z. Young,
V. C. Soares,
R. Kelley,
R. Benezra, and Y. Zhuang.
1997.
High incidence of acute T-cell tumors in E2A-null mice and E2A/Id1 double knockout mice.
Mol. Cell. Biol.
17:7317-7327[Abstract].
|
| 69.
|
Zelazowski, P.,
J. T. Collins,
W. Dunnick, and C. M. Snapper.
1995.
Antigen receptor cross-linking differentially regulates germ-line CH ribonucleic acid expression in murine B cells.
J. Immunol.
154:1223-1231[Abstract].
|
| 70.
|
Zhuang, Y.,
R. J. Bardnt,
L. Pan,
R. Kelley, and M. Dai.
1998.
Functional replacement of the mouse E2A gene with a human HEB cDNA.
Mol. Cell. Biol.
18:3340-3349[Abstract/Free Full Text].
|
| 71.
|
Zhuang, Y.,
P. Cheng, and H. Weintraub.
1996.
B-lymphocyte development is regulated by the combined dosage of three basic helix-loop-helix genes, E2A, E2-2, and HEB.
Mol. Cell. Biol.
16:2898-2905[Abstract].
|
| 72.
|
Zhuang, Y.,
P. Soriano, and H. Weintraub.
1994.
The helix-loop-helix gene E2A is required for B cell formation.
Cell
79:875-884[Medline].
|
Molecular and Cellular Biology, September 1999, p. 5969-5980, Vol. 19, No. 9
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
del Blanco, B., Roberts, J. L., Zamarreno, N., Balmelle-Devaux, N., Hernandez-Munain, C.
(2009). Flexible Stereospecific Interactions and Composition within Nucleoprotein Complexes Assembled on the TCR{alpha} Gene Enhancer. J. Immunol.
183: 1871-1883
[Abstract]
[Full Text]
-
Yashiro-Ohtani, Y., He, Y., Ohtani, T., Jones, M. E., Shestova, O., Xu, L., Fang, T. C., Chiang, M. Y., Intlekofer, A. M., Blacklow, S. C., Zhuang, Y., Pear, W. S.
(2009). Pre-TCR signaling inactivates Notch1 transcription by antagonizing E2A. Genes Dev.
23: 1665-1676
[Abstract]
[Full Text]
-
Kumar, D., Shadrach, J. L., Wagers, A. J., Lassar, A. B.
(2009). Id3 Is a Direct Transcriptional Target of Pax7 in Quiescent Satellite Cells. Mol. Biol. Cell
20: 3170-3177
[Abstract]
[Full Text]
-
Ueda-Hayakawa, I., Mahlios, J., Zhuang, Y.
(2009). Id3 Restricts the Developmental Potential of {gamma}{delta} Lineage during Thymopoiesis. J. Immunol.
182: 5306-5316
[Abstract]
[Full Text]
-
Sellam, J., Miceli-Richard, C., Gottenberg, J.-E., Proust, A., Ittah, M., Lavie, F., Loiseau, P., Mariette, X.
(2008). Is Inhibitor of differentiation 3 involved in human primary Sjogren's syndrome?. Rheumatology (Oxford)
47: 437-441
[Abstract]
[Full Text]
-
Koltsova, E. K., Ciofani, M., Benezra, R., Miyazaki, T., Clipstone, N., Zuniga-Pflucker, J. C., Wiest, D. L.
(2007). Early Growth Response 1 and NF-ATc1 Act in Concert to Promote Thymocyte Development beyond the beta-Selection Checkpoint. J. Immunol.
179: 4694-4703
[Abstract]
[Full Text]
-
Perry, S. S., Zhao, Y., Nie, L., Cochrane, S. W., Huang, Z., Sun, X.-H.
(2007). Id1, but not Id3, directs long-term repopulating hematopoietic stem-cell maintenance. Blood
110: 2351-2360
[Abstract]
[Full Text]
-
Jones, J. M., Montcouquiol, M., Dabdoub, A., Woods, C., Kelley, M. W.
(2006). Inhibitors of Differentiation and DNA Binding (Ids) Regulate Math1 and Hair Cell Formation during the Development of the Organ of Corti. J. Neurosci.
26: 550-558
[Abstract]
[Full Text]
-
Leeanansaksiri, W., Wang, H., Gooya, J. M., Renn, K., Abshari, M., Tsai, S., Keller, J. R.
(2005). IL-3 Induces Inhibitor of DNA-Binding Protein-1 in Hemopoietic Progenitor Cells and Promotes Myeloid Cell Development. J. Immunol.
174: 7014-7021
[Abstract]
[Full Text]
-
Hata, K., Yoshimoto, T., Mizuguchi, J.
(2004). CD40 Ligand Rescues Inhibitor of Differentiation 3-Mediated G1 Arrest Induced by Anti-IgM in WEHI-231 B Lymphoma Cells. J. Immunol.
173: 2453-2461
[Abstract]
[Full Text]
-
Liu, C.-j., Ding, B., Wang, H., Lengyel, P.
(2002). The MyoD-Inducible p204 Protein Overcomes the Inhibition of Myoblast Differentiation by Id Proteins. Mol. Cell. Biol.
22: 2893-2905
[Abstract]
[Full Text]
-
Ehrlich, M., Buchanan, K. L., Tsien, F., Jiang, G., Sun, B., Uicker, W., Weemaes, C. M.R., Smeets, D., Sperling, K., Belohradsky, B. H., Tommerup, N., Misek, D. E., Rouillard, J.-M., Kuick, R., Hanash, S. M.
(2001). DNA methyltransferase 3B mutations linked to the ICF syndrome cause dysregulation of lymphogenesis genes. Hum Mol Genet
10: 2917-2931
[Abstract]
[Full Text]
-
Engel, I., Johns, C., Bain, G., Rivera, R. R., Murre, C.
(2001). Early Thymocyte Development Is Regulated by Modulation of E2a Protein Activity. JEM
194: 733-746
[Abstract]
[Full Text]
-
Norton, J.
(2000). ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J. Cell Sci.
113: 3897-3905
[Abstract]
-
BARNDT, R.J., ZHUANG, Y.
(1999). Controlling Lymphopoiesis with a Combinatorial E-protein Code. Cold Spring Harb Symp Quant Biol
64: 45-50
[Abstract]